Clinical Trial Update: Effect of Rasagiline on BIA 9-1067 Pharmacokinetics [Phase 1]

View source ↗

Summary

Phase 1 study assessing the effect of rasagiline on the pharmacokinetics of BIA 9-1067 in Parkinson disease; results have been posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• BIA 9-1067
• RASAGILINE (rasagiline)

Snippet

Sponsor: Bial - Portela C S.A. | Conditions: Parkinson Disease | Phase 1 | Status: COMPLETED | Results posted: 2015-08-20